Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

413 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma.
Levis A, Pietrasanta D, Godio L, Vitolo U, Ciravegna G, Di Vito F, Gavarotti P, Guglielmelli T, Orsucci L, Raviolo E, Rota Scalabrini D, Salvi F, Tonso A, Aglietta M, Boccadoro M, Gallamini A, Saglio G, Scassa E, Gallo E. Levis A, et al. Among authors: salvi f. Clin Lymphoma. 2004 Jun;5(1):50-5. doi: 10.3816/clm.2004.n.010. Clin Lymphoma. 2004. PMID: 15245608
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A. Zallio F, et al. Among authors: salvi f. Br J Haematol. 2016 Mar;172(6):879-88. doi: 10.1111/bjh.13904. Epub 2016 Jan 13. Br J Haematol. 2016. PMID: 26763986 Free article. Clinical Trial.
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study.
Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D. Messa E, et al. Among authors: salvi f. Leuk Lymphoma. 2017 Nov;58(11):2752-2754. doi: 10.1080/10428194.2017.1312385. Epub 2017 May 9. Leuk Lymphoma. 2017. PMID: 28482720 Free article. No abstract available.
Low-dose of thalidomide in the treatment of refractory myeloma.
Pini M, Baraldi A, Pietrasanta D, Allione B, Depaoli L, Salvi F, Levis A. Pini M, et al. Among authors: salvi f. Haematologica. 2000 Oct;85(10):1111-2. Haematologica. 2000. PMID: 11025615 Clinical Trial. No abstract available.
VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.
Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F; Intergruppo Italiano Linfomi (IIL). Levis A, et al. Among authors: salvi f. Ann Oncol. 2004 Jan;15(1):123-8. doi: 10.1093/annonc/mdh012. Ann Oncol. 2004. PMID: 14679131 Free article.
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
Zaja F, Salvi F, Rossi M, Sabattini E, Evangelista A, Ciccone G, Angelucci E, Gaidano G, Zanni M, Ladetto M, Chiappella A, Vitolo U, Zinzani PL, Califano C, Tucci A, Patti C, Pileri SA, Lenti V, Piccaluga PP, Cavallo F, Volpetti S, Perali G, Assouline S, Mann KK, Morin R, Alcaide M, Bushell K, Fanin R, Levis A. Zaja F, et al. Among authors: salvi f. Leuk Lymphoma. 2018 Dec;59(12):2904-2910. doi: 10.1080/10428194.2018.1452208. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616865 Clinical Trial.
413 results